Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Recall Issued for Roche Elecsys Troponin Immunoassay

by Global Biodefense Staff
April 24, 2012

The U.S. Food and Drug Administration (FDA) listed Roche Diagnostics today on the agency’s Class 1 Medical Devices Recall List. The products in question are Roche Elecsys Troponin I and Elecsys Troponin I STAT Immunoassays distributed between June 29, 2011 and January 13, 2012. 

The recall cites that certain types of plasma samples used with the assays may produce falsely low results up to a maximum of 50% lower than the actual concentration of Troponin I.  Incorrect results such as these “may cause serious adverse health consequences, including death.”

Roche has issued letters to customers known to have received the products in question with reporting and disposal instructions.

Class I recalls are the most serious type of recall and involve situations in which there is a reasonable probability that use of these products will cause serious adverse health consequences or death. Troponin biomarker tests in general are frequently utilized to assess cardiac injury such as a heart attack, and to distinguish chest pain that may be due to other causes.

Health care professionals and consumers may report adverse reactions or quality problems they experienced using these products to the MedWatch FDA Safety Information and Adverse Event Reporting Program either online, by regular mail, by telephone, or by FAX.

Specific lot numbers for recalled products are available at the FDA Medical Device List of Recalls page.

Tags: Biomarkers

Related Posts

small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
Much of the CDC is Working Remotely. That Could Make Changing the Agency Difficult.
Policy + Initiatives

Much of the CDC is Working Remotely. That Could Make Changing the Agency Difficult.

December 7, 2022
Study: Cash Incentives and Lotteries Do Little to Increase Adult Vaccinations
Medical Countermeasures

Study: Cash Incentives and Lotteries Do Little to Increase Adult Vaccinations

October 25, 2022
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC